Is Tempus worth it for a large oncology program?

It depends on whether you already generate molecular data. If you do, Tempus xT's 648-gene DNA/RNA panel feeds directly into EHR-integrated decision support, and the 7M+ de-identified record library powers trial matching and outcome prediction from the same platform. If you don't, the platform has less to work with. For high-volume oncology programs it is one of the few places doing sequencing and real-world evidence together.

How does Tempus compare to Foundation Medicine?

Foundation Medicine is the profiling-first option: comprehensive genomic profiling as the core product. Tempus runs the same kind of sequencing through Tempus xT but pairs it with a 7M+ de-identified clinical record library, Tempus LENS analytics and pharma-facing real-world evidence. If you want profiling and nothing else, Foundation Medicine is the tighter fit. If you want profiling plus the analytics layer attached, Tempus plays in both lanes.

How does Tempus compare to Flatiron Health?

Flatiron is the real-world evidence specialist. Tempus also generates real-world evidence via Tempus LENS and its 7M+ de-identified record library, but it adds its own sequencing arm through the 648-gene xT panel and EHR-integrated decision support. Choose Flatiron if evidence generation is the whole job and sequencing stays elsewhere; choose Tempus if you want both under one vendor.

Can Tempus replace Foundation Medicine?

For the sequencing step, yes in principle — Tempus xT covers 648 genes across tumor DNA and RNA, which is the same job a profiling-first lab does. The real question is whether you want the surrounding platform: trial matching, outcome prediction and the de-identified record library. If all you need is a genomic profile, paying for Tempus's broader platform is unnecessary. If you want profiling to feed decision support, it replaces the standalone lab relationship.

What are Tempus's biggest limitations?

Its center of gravity is oncology. Tempus Pixel, ECG-AI and Tempus PRO are real but secondary modules. Deployment is an enterprise integration project — the content notes integration can require dedicated IT support — and the platform's value depends on your institution already producing molecular and clinical data. There is no direct-to-consumer path for patients.

Is Tempus good for matching patients to clinical trials?

Yes — trial matching is one of the platform's core functions, not an add-on. It runs on the same data foundation as treatment selection: Tempus xT returns the genomic alterations, and the 7M+ de-identified record library and 8,000+ clinician network provide the real-world context for identifying open trials. Because it is EHR-integrated, the match appears inside the physician's existing workflow.

Does Tempus work for specialties outside oncology?

Partly. Tempus Pixel evaluates radiology therapy response, ECG-AI flags underdiagnosed cardiovascular patients, and Tempus PRO handles AI-assisted notetaking for neurologists. Those are genuine products, but they sit alongside a company whose core is cancer care. A cardiology or neurology team evaluating Tempus is buying a secondary module from an oncology platform, and should weigh that in procurement.

How long does Tempus take to set up?

Sequencing and decision support are the natural starting point for an oncology program that already generates molecular data; LENS analytics and research data access come later. The slow part is connecting EHR and data pipelines, which the content notes may require dedicated IT support. Radiology, cardio and neurology modules typically follow as pilots. Budget weeks of integration work, not days.

Is Tempus free for researchers?

There is no free research tier described in the available material — Research is a quoted plan alongside Clinical, covering Tempus LENS cloud analytics, de-identified record access across 7M+ records, AI model building tools and pharmaceutical research data access. Academic and pharma groups negotiate scope and data-access terms directly with the vendor rather than signing up self-serve.

How do I migrate from Foundation Medicine to Tempus?

The move is less a data migration than a workflow shift: start ordering Tempus xT in place of your existing comprehensive genomic profiling, and connect the results to EHR-integrated decision support so trial matching and outcome prediction come online. Your historical profiling data stays where it is. The heavy lift is the EHR and pipeline integration, which the content notes may require dedicated IT support.

Healthcare

Tempus

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

73/100Safe BetCustom pricingContact Sales

If your oncology program already produces molecular data and wants it turned into trial matches and outcome signal, Tempus is one of the few vendors doing sequencing plus real-world evidence in one pipeline. The constraint is fit rather than quality: pricing runs through a custom quote, so a small independent clinic will find it oversized and slow to justify. We'd pick it over Foundation Medicine when the data asset matters as much as the report, and over Flatiron when you also need the lab.

Verified 5d ago · liveness 73/100 · cite: rightaichoice.com/tools/tempus

Best for

Oncology programs in large health systems needing AI-driven treatment and trial matching
Pharmaceutical companies requiring real-world evidence for drug development
Cancer researchers analyzing large-scale de-identified patient data
Academic medical centers with informatics capacity for molecular profiling

Not ideal for

Small independent clinics without enterprise budget or IT staff
Patients seeking direct-to-consumer genetic testing
Providers who only need a simple single-gene test

Visit Website

AdvancedOncology programs already generating molecular and clinical data can usually start with sequencing and decision support first, with LENS analytics and research data access layered on later. Expect the EHR and pipeline connection to be the slow part — the content notes integration may require dedicated IT support. Radiology, cardio and neurology modules are typically pilots that follow the coreWeb · APIAPI available4.3k viewsVerified 5d ago

Pricing

Custom pricing

Contact Sales2 plans3 hidden costs

Learning curve

Advanced

Oncology programs already generating molecular and clinical data can usually start with sequencing and decision support first, with LENS analytics and research data access layered on later. Expect the EHR and pipeline connection to be the slow part — the content notes integration may require dedicated IT support. Radiology, cardio and neurology modules are typically pilots that follow the core

Runs on

WebAPI

API available

Who it's for

Oncologist at a large health systemPharma real-world evidence leadRadiology or cardiology team at an academic center

Live sentiment

Is Tempus actually worth it?

We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.

Honest verdict, not marketing
Real pros & cons from real users
Attributed quotes with receipts

Run a free scan

3 free scans · no card needed

Skip it if

Skip Tempus if you are a small independent clinic that only needs a single-gene test, or if you have no existing molecular or clinical data pipeline to feed into the platform.

The 30-second take

Biggest gripe

Clinical and Research plans are quoted, so your real cost depends on modules, data-access terms and scope negotiated with the vendor rather than a published rate card.

Price reality

Tempus prices by quote across two published tracks: Clinical (sequencing, EHR-integrated decision support, trial matching, Pixel, PRO) and Research (LENS analytics, real-world evidence, de-identified record access, model building). The shape of the commitment fits large health systems, academic medical centers and pharma research groups. Small independent clinics and single-gene-test buyers are not the intended customer and should look at profiling-only vendors instead.

In short

Tempus — Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches. Best for Oncology programs in large health systems needing AI-driven treatment and trial matching, Pharmaceutical companies requiring real-world evidence for drug development, Cancer researchers analyzing large-scale de-identified patient data. Contact Sales pricing.

No head-to-head comparison for Tempus yet — the alternatives below are the closest matches we list.

What people actually say about Tempus — is it worth it?

We scanned public community sources for Tempus on Sep 22, 2026 and could not establish that the discussion we found is about this tool rather than something else sharing its name. Only 1 of the posts we fetched could be positively tied to Tempus. Rather than publish a sentiment score built on the wrong subject, we publish nothing here and re-run the scan.

Viability Score

73/100

Safe Bet

How well maintained and how widely used is Tempus? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this

Recent activity

not measured

Traction

100

Site health

User sentiment

What the vendor publishes

Last calculated: October 2026

How we score →

Key Features

Tempus xT DNA/RNA sequencing panel covering 648 genes
Genomic alteration detection across tumor DNA and RNA
EHR-integrated physician decision support at point of care
Clinical trial matching for oncology patients
Treatment outcome prediction from multimodal patient data
De-identified patient record library with 7M+ clinical records
Clinician network spanning 8,000+ providers
Multimodal data integration across genomic, clinical and imaging sources
Tempus LENS cloud analytics for real-world evidence generation
AI model building tools for research teams
Tempus Pixel radiology therapy response evaluation
ECG-AI for cardiovascular patient identification
Tempus PRO AI-assisted notetaking for neurologists
Pharmaceutical research data access for drug discovery

About Tempus

Contact SalesAdvancedAPI availableWeb · API

Tempus is a health technology company whose core product is AI precision oncology: it sequences tumor DNA and RNA, then runs those molecular results through a clinical and imaging data engine so oncologists can see treatment and trial options next to the genomic profile. The sequencing layer is the Tempus xT panel, which covers 648 genes across DNA and RNA; results feed EHR-integrated physician decision support rather than landing in a standalone PDF. What separates it from a pure lab is the surrounding data asset. Tempus works from a de-identified library of more than 7 million clinical records and a network of 8,000+ clinicians, and it uses that corpus for treatment outcome prediction and clinical trial matching. Genomic, clinical and imaging data are analyzed together, which is the whole point of the architecture. The same engine stretches into adjacent specialties. Tempus Pixel evaluates radiology therapy response, ECG-AI flags underdiagnosed cardiovascular patients, and Tempus PRO handles AI-assisted notetaking for neurologists. For research teams, Tempus LENS provides a cloud analytics layer for real-world evidence generation and model building, and pharmaceutical partners tap the same corpus for drug discovery work. This is an enterprise commitment, not a single-gene test you order once. It fits institutions already generating molecular and clinical data and looking to convert it into trial matches and outcome signal. Compare Foundation Medicine when profiling is the only need, and Flatiron Health when real-world evidence generation is the entire job.

Behind the Verdict

The interesting thing about Tempus isn't the panel — plenty of labs sequence tumor DNA and RNA. It's that the results land inside a decision-support layer wired to a de-identified library of 7M+ clinical records and a clinician network of 8,000+. That combination is what makes treatment outcome prediction and trial matching possible at a scale a single institution can't build alone. Pick Tempus when your oncology program is already generating molecular data and you want it converted into something actionable at the point of care. The EHR-integrated decision support is the practical hook — an oncologist sees trial options beside the molecular profile instead of hunting for them. Pass when profiling is the whole job and you don't need the outcome data. Foundation Medicine covers that ground. If real-world evidence generation is the entire scope, Flatiron Health is the more direct fit. In practice, the modules are the part buyers underrate. Tempus Pixel for radiology therapy response, ECG-AI for cardiovascular patient identification, Tempus PRO for neurologist notetaking — each extends the same data engine into a different specialty, which matters if you're buying for a health system rather than a single department. Where it bites: this is an enterprise deployment. Pricing is quoted per engagement, so budget cycles and legal review will shape the timeline as much as the technology does. Small independent clinics without IT staff should look elsewhere — the platform assumes your institution is already producing molecular and clinical data to feed it. We'd also flag that the value compounds with data volume. An institution contributing little gets less out of the outcome models than a large academic medical center does. That's not a flaw, just how the model works. For

Researching Tempus? Get your full AI stack in 60 seconds.

Free, no signup — tell us your goal and get tools matched to your budget & existing stack.

Real-world workflow fit

Concrete scenarios for the personas Tempus actually fits — and what changes day-one when you adopt it.

Oncologist at a large health system

You order Tempus xT for a patient whose tumor has progressed on standard therapy. The 648-gene DNA/RNA panel returns actionable alterations, and because the result flows into EHR-integrated decision support you see targeted therapy options and open clinical trials in the same place you chart.

Outcome: Treatment selection and trial matching happen in one pass instead of two separate referral chains.

Pharma real-world evidence lead

Your team needs external control data for a drug program. You query the de-identified library of 7M+ clinical records through Tempus LENS, generate real-world evidence, and use the built-in model building tools to test your hypothesis before committing to a prospective study.

Outcome: You get an evidence signal from existing patient data rather than waiting on a new trial to read out.

Radiology or cardiology team at an academic center

Your oncology colleagues already run Tempus, and your department pilots the adjacent modules — Tempus Pixel to evaluate therapy response on imaging, or ECG-AI to surface underdiagnosed cardiovascular patients from existing ECG data.

Outcome: You reuse the institution's existing Tempus relationship to add imaging and cardiac signal without a separate vendor procurement.

Use Cases

Identifying targeted therapies for cancer patients based on genomic profiling
Matching patients to clinical trials using AI and real-world data
Accelerating drug discovery with real-world evidence for pharma partners
Closing care gaps in oncology through AI-enabled analytics
Supporting neurologists with AI-assisted notetaking (Tempus PRO)
Identifying underdiagnosed cardiovascular patients using ECG-AI
Evaluating therapy response in radiology with Tempus Pixel
Providing de-identified data access for cancer research

Models Under the Hood

Proprietary AI models for genomic analysisAI models for treatment outcome predictionAI models for clinical trial matching

as of 2026-08-31

Limitations

The platform's center of gravity is oncology; ECG-AI and Tempus PRO are meaningful but secondary modules rather than the reason most institutions buy.
Deployment is an enterprise integration project, and the content notes that integration can require dedicated IT support.
Value depends on your institution already generating molecular and clinical data to feed the platform — there is no direct-to-consumer path for patients.
Commercial terms are quoted rather than published, so total cost depends on scope, modules and data-access terms negotiated with the vendor.

as of 2026-10-01

Verification history

We have re-verified Tempus 21 times since May 24, 2026. Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.

Oct 12, 2026 — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Sep 28, 2026 — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Sep 22, 2026 — re-checked, vendor evidence unchanged
Aug 30, 2026 — re-checked, vendor evidence unchanged
Aug 24, 2026 — re-checked, vendor evidence unchanged
Aug 7, 2026 — re-checked, vendor evidence unchanged

Showing the 6 most recent of 21 verification passes.

Free to cite with attribution — this page re-verifies continuously.

12-month cost

Project the real annual outlay, including the implied monthly cost when only an annual tier is published.

Plan

Annual total

—

Contact sales for a quote

Effective monthly

—

Vendor list price only. Add-on usage, seat overages, and contract minimums are surfaced under Hidden costs & gotchas.

Plans compared

For each published Tempus tier: who it actually fits, and what it adds vs. the previous tier. Cross-reference the cost calculator above for projected annual outlay.

Clinical

Custom

Ideal for

Oncology programs in large health systems and academic medical centers already ordering molecular profiling for a patient population.

What this tier adds

Starting tier: genomic sequencing via Tempus xT, EHR-integrated decision support, trial matching, plus Pixel and PRO modules.

Research

Custom

Ideal for

Pharmaceutical research teams and academic groups that need real-world evidence and de-identified patient data at scale.

What this tier adds

Adds Tempus LENS cloud analytics, de-identified record access (7M+ records), AI model building tools and pharma research data access.

Hidden costs & gotchas

What the public pricing page doesn't put in bold. Captured from pricing-page footnotes, contract terms, and recurring complaints.

Clinical and Research plans are quoted, so your real cost depends on modules, data-access terms and scope negotiated with the vendor rather than a published rate card.
Bringing the platform online inside a health system is an integration project, and the IT work to connect EHR and data pipelines lands on your team, not the vendor's.
Research-side value depends on de-identified record access and analytics scope, which are contracted separately from the clinical sequencing relationship — budget for both if you want the full picture.

Where the pricing makes sense

The company stage and team size where Tempus's pricing actually pencils out — and where peers do it cheaper.

Setup time & first value

How long it actually takes to get something useful out of Tempus — broken out by persona, not the marketing-page minute.

Switching to or from Tempus

How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.

Migrating in

→From Foundation Medicine: move profiling-first workflows onto Tempus if you also want trial matching and real-world evidence from the same vendor rather than a separate analytics relationship.
→From Flatiron Health: move to Tempus if you want genomic sequencing and evidence generation under one roof instead of evidence generation alone.

Migrating out

↗To Foundation Medicine: if comprehensive genomic profiling is the whole job and you do not need the 7M+ record analytics layer.
↗To Flatiron Health: if real-world evidence generation is the entire requirement and sequencing stays with a separate lab.

Resources & Guides

Tutorials & Learning

YouTube returned 6 videos for “Tempus”, and we withheld 6: 6 could not be judged, because “Tempus” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about Tempus.